- Athens 2019
- Paris 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: LASIK
Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30
Paper Time: 09:52
Venue: Auditorium (First Floor)
First Author: : M.Rosman SINGAPORE
Co Author(s): : J. Mehta C. Chan
To compare the refractive outcomes, efficacy and predictability of FemtoLASIK in myopic eyes with astigmatism of -2.0D or more using the Visumax500 kHz Femtosecond (Carl Zeiss Meditec AG, Jena, Germany) laser platform versus the Intralase 60kHz Femtosecond (Abbott Medical Optics Inc, Santa Ana, USA) laser platform.
A multi-surgeon national eye centre
A retrospective study of consecutive myopic eyes with astigmatism of -2.0D or more, with a follow-up of at least 3 months post-surgery, which have undergone FemtoLASIK from 2007 to 2012. 308 eyes had corneal flap creation using the Intralase femtosecond laser platform and 548 eyes had corneal flap creation using the Visumax femtosecond laser platform. All eyes underwent excimer laser ablation using the Wavelight Allegretto Eye-Q 400Hz excimer laser system (Wavelight AG, Erlangen, Germany). Target refraction was emmetropia.
The mean spherical equivalent 3 months post-surgery was 0.03 D in the Intralase group and -0.01 D in the Visumax group (p>0.05). The mean cylinder was -0.40D in the Intralase group and 0.43D in the Visumax group (p>0.05). 61.6% of eyes in the Intralase group achieved unaided visual acuity of 20/20 compared to 68.1% in the Visumax group (p>0.05). The efficacy index of the Intralase group was 0.92 and the efficacy index was 0.93 in the Visumax group. 82.7% of eyes in the Intralase group were within +/-0.5D of intended correction compared to 86.4% in the Visumax group (p>0.05). 2 eyes lost 2 lines of best corrected visual acuity in both the Intralase (1.1%) and the Visumax group (0.6%). The safety index was 1.07 for both groups.
Femto-LASIK with the Intralase and Visumax platforms produce good refractive outcomes in myopic eyes with astigmatism of -2.0D or higher. Both machines result in similar efficacy, predictability and safety outcomes.
Please wait while information is loading.